Angiotensin (1-7) vs Sermorelin

Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.

A heptapeptide formed from angiotensin II via ACE2 cleavage, or from angiotensin I via neprilysin. Acts as the endogenous counter-regulatory axis to angiotensin II — producing vasodilation, anti-fibrotic, and metabolic benefits via the Mas receptor.

Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH secretion in a physiological pattern that preserves the natural hypothalamic-pituitary feedback axis — contrasting with direct GH administration. Downstream IGF-1 elevation mediates many of its body composition, tissue-repair, and sleep quality effects.

Sermorelin is a GHRH analogue used to stimulate endogenous growth hormone production. It is one of the most widely prescribed peptides in the anti-aging and functional medicine space, valued for preserving the natural pituitary feedback axis while supporting body composition, sleep quality, and tissue repair. Compounded formulations are available in the US through 503A pharmacies.